After the pharmaceutical industry spent much of the past year safeguarding its businesses against the threat of U.S.
Supreme Court curtailed parts of the administration's tariff authority, reducing immediate tariff risk for pharmaceutical importers.
Why it mattersSupreme Court ruling blocking portions of tariff authority prevented imminent import tariffs, easing immediate cost pressures for drugmakers.